Manufacturer of Controlled Substances; Notice of Application, 36679-36680 [2010-15516]

Download as PDF 36679 Federal Register / Vol. 75, No. 123 / Monday, June 28, 2010 / Notices opportunity were permitted to appear in person or by counsel. The Commission transmitted its determinations in these investigations to the Secretary of Commerce on June 22, 2010. The views of the Commission are contained in USITC Publication 4162 (June 2010), entitled Prestressed Concrete Steel Wire Strand from China: Investigation Nos. 701–TA–464 and 731–TA–1160 (Final). By order of the Commission. Issued: June 23, 2010. Marilyn R. Abbott, Secretary to the Commission. Secretary of Commerce on June 22, 2010. The views of the Commission are contained in USITC Publication 4160 (June 2010), entitled Polyethylene Retail Carrier Bags from China, Malaysia, and Thailand: Investigation Nos. 731–TA– 1043–1045 (Review). By order of the Commission. Issued: June 22, 2010. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. 2010–15664 Filed 6–25–10; 8:45 am] BILLING CODE 7020–02–P [FR Doc. 2010–15660 Filed 6–25–10; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE INTERNATIONAL TRADE COMMISSION Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act [Investigation Nos. 731–TA–1043–1045 (Review)] Polyethylene Retail Carrier Bags From China, Malaysia, and Thailand; Determinations jlentini on DSKJ8SOYB1PROD with NOTICES On the basis of the record 1 developed in the subject five-year reviews, the United States International Trade Commission (Commission) determines, pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. 1675(c)), that revocation of the antidumping duty orders on polyethylene retail carrier bags from China, Malaysia, and Thailand would be likely to lead to continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time. Background The Commission instituted these reviews on July 1, 2009 (74 FR 31750, July 2, 2009) and determined on October 5, 2009 that it would conduct full reviews (74 FR 54069, October 21, 2009). Notice of the scheduling of the Commission’s reviews and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register on November 23, 2009 (74 F.R. 61172). The hearing was held in Washington, DC, on April 27, 2010, and all persons who requested the opportunity were permitted to appear in person or by counsel. The Commission transmitted its determinations in these reviews to the 1 The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)). VerDate Mar<15>2010 21:02 Jun 25, 2010 Jkt 220001 Notice is hereby given that on June 22, 2010, a proposed Consent Decree in United States and Commonwealth of Pennsylvania Department of Environmental Protection v. Williamsport Sanitary Authority, Civil Action No. 4:10–cv–01304 was lodged with the United States District Court for the Middle District of Pennsylvania. The proposed Consent Decree, lodged on June 22, 2010, resolves the liability of defendant Williamsport Sanitary Authority (‘‘WSA’’) for violations of the Clean Water Act, 42 U.S.C. and the Pennsylvania Clean Streams Act, 35 P.S. §§ 691.1 et seq. alleged in a Complaint filed on June 22, 2010. The Consent Decree requires WSA to expand the treatment capacity of its Central Wastewater Treatment Plant and to increase its storage capacity to cope with high flow during wet weather to guard against combined sewer overflows to the West Branch of the Susquehanna River. WSA has also agreed to pay a civil penalty of $160,000 to the United States and $160,000 to the Pennsylvania Department of Environmental Protection. The Department of Justice will receive comments relating to the proposed Consent Decree for a period of thirty (30) days from the date of this publication. Please address comments to the Assistant Attorney General, Environment and Natural Resources Division, by e-mail to pubcommentees.enrd@usdoj.gov or regular mail to P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and refer to United States and Commonwealth of Pennsylvania Department of Environmental Protection v. Williamsport Sanitary Authority, D.J. Ref. 90–5–1–1–09293. PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 The Consent Decree may be examined at the Office of the United States Attorney for the Middle District of Pennsylvania, Harrisburg Federal Building and Courthouse, 228 Walnut Street, Suite 220, Harrisburg, PA,11754 and at U.S. EPA Region III, 1650 Arch Street, Philadelphia, PA 19103. During the public comment period, the Consent Decree may also be examined on the following Department of Justice Web site, https://www.usdoj.gov/enrd/ consent_decrees.html. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514–0097, phone confirmation number (202) 514–1547. When requesting a copy from the Consent Decree Library, please enclose a check in the amount of $15.75 for the Consent Decree only or $262.00 for the Consent Decree and attachments (25 cents per page reproduction cost) payable to the U.S. Treasury or, if by email or fax, forward a check in that amount to the Consent Decree Library at the address above. Maureen Katz, Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2010–15548 Filed 6–25–10; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 8, 2010, Lin Zhi International Inc., 670 Almanor Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Tetrahydrocannabinols (7370) ...... 3,4– Methylenedioxymethamphetamine (MDMA) (7405). Cocaine (9041) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). E:\FR\FM\28JNN1.SGM 28JNN1 Schedule I I II II II II II 36680 Federal Register / Vol. 75, No. 123 / Monday, June 28, 2010 / Notices Drug Schedule Morphine (9300) ........................... II The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 27, 2010. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application This is notice that on March 31, 2010, Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II: Schedule jlentini on DSKJ8SOYB1PROD with NOTICES 21:02 Jun 25, 2010 BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on April 20, 2010, United States Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, Maryland 20852, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II: II II Drug The company imports the listed controlled substances in order to bulk manufacture controlled substances in Active Pharmaceutical Ingredient (API) form. The company distributes the manufactured APIs in bulk form only to its customers. As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate. As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a VerDate Mar<15>2010 [FR Doc. 2010–15522 Filed 6–25–10; 8:45 am] Importer of Controlled Substances; Notice of Application [FR Doc. 2010–15516 Filed 6–25–10; 8:45 am] Raw Opium (9600) ....................... Concentrate of Poppy Straw (9670). Dated: June 17, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Drug Enforcement Administration Dated: June 17, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Drug basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b),(c),(d),(e), and (f) are satisfied. Jkt 220001 Schedule Cathinone (1235) .......................... Methaqualone (2565) ................... Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... 4-Methyl-2,5-dimethoxy-amphetamine (7395). 3,4-Methylenedioxy amphetamine (7400). Codeine-N–Oxide (9053) ............. Heroin (9200) ............................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Phenmetrazine (1631) .................. Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Phencyclidine (7471) .................... Alphaprodine (9010) ..................... Anileridine (9020) ......................... Cocaine (9041) ............................. PO 00000 Frm 00052 Fmt 4703 Sfmt 9990 I I I I I I I I II II II II II II II II II II II II Drug Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Alfentanil (9737) ........................... Sufentanil (9740) .......................... Schedule II II II II II II II II II II II II II II II II The company plans to import reference standards for sale to researchers and analytical labs. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 28, 2010. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: June 17, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–15519 Filed 6–25–10; 8:45 am] BILLING CODE 4410–09–P E:\FR\FM\28JNN1.SGM 28JNN1

Agencies

[Federal Register Volume 75, Number 123 (Monday, June 28, 2010)]
[Notices]
[Pages 36679-36680]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-15516]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 8, 2010, Lin Zhi 
International Inc., 670 Almanor Avenue, Sunnyvale, California 94085, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)................  I
3,4-Methylenedioxymethamphetamine (MDMA)      I
 (7405).
Cocaine (9041)..............................  II
Oxycodone (9143)............................  II
Hydrocodone (9193)..........................  II
Methadone (9250)............................  II
Dextropropoxyphene, bulk (non-dosage forms)   II
 (9273).

[[Page 36680]]

 
Morphine (9300).............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
as bulk reagents for use in drug abuse testing.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than August 27, 2010.

    Dated: June 17, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-15516 Filed 6-25-10; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.